# EDGAR Filing Document

**Accession Number:** 0000895464
**File Stem:** 0001640334-25-001321
**Filing Date:** 2025-7
**Character Count:** 10417
**Document Hash:** da7cf1d9c3648f5098944e45d86fa919
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001640334-25-001321.hdr.sgml**: 20250725

**ACCESSION NUMBER**: 0001640334-25-001321

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250725

**DATE AS OF CHANGE**: 20250725

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Yubo International Biotech Ltd
- **CENTRAL INDEX KEY:** 0000895464
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 113074326
- **STATE OF INCORPORATION:** NY
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-52079
- **FILM NUMBER:** 251151785

**BUSINESS ADDRESS:**
- **STREET 1:** ROOM 105, BUILDING 5, 31 XISHIKU AVENUE
- **CITY:** BEIJING
- **STATE:** F4
- **ZIP:** 00000
- **BUSINESS PHONE:** 86 (010) 6615-5141

**MAIL ADDRESS:**
- **STREET 1:** ROOM 105, BUILDING 5, 31 XISHIKU AVENUE
- **CITY:** BEIJING
- **STATE:** F4
- **ZIP:** 00000

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MAGNA LAB INC
- **DATE OF NAME CHANGE:** 19940722
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Flydragon International Ltd
- **CENTRAL INDEX KEY:** 0001841458

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** C/O YUBO INTERNATIONAL BIOTECH LIMITED
- **STREET 2:** ROOM 105, BUILDING 5, 31 XISHIKU AVENUE
- **CITY:** XICHENG DISTRICT, BEIJING
- **STATE:** F4
- **ZIP:** 00000
- **BUSINESS PHONE:** 86 010 6615 5141

**MAIL ADDRESS:**
- **STREET 1:** C/O YUBO INTERNATIONAL BIOTECH LIMITED
- **STREET 2:** ROOM 105, BUILDING 5, 31 XISHIKU AVENUE
- **CITY:** XICHENG DISTRICT, BEIJING
- **STATE:** F4
- **ZIP:** 00000

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**Yubo International Biotech Limited**

*(Name of Issuer)*

**Class A Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**988366100**

*(CUSIP Number)*

**Flydragon International Ltd**<br>Wickham's Cay II<br>P.O. Box 2221, Road Town<br>Tortola D8 00000<br>86 136-0129-6655

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**07/23/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **988366100** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Flydragon International Ltd** | Name of reporting person<br>**Flydragon International Ltd** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**D8** | Citizenship or place of organization<br>**D8** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**81943800.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**81943800.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**81943800.00** | Aggregate amount beneficially owned by each reporting person<br>**81943800.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**48.1%** | Percent of class represented by amount in Row (11)<br>**48.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

**Comment for Reporting Person:** Comment for Percent of class represented by amount in Row (11): This percentage is based on an aggregate of 170,416,343 shares of Class A Common Stock, consisting of (i) 119,816,343 shares of Class A Common Stock outstanding as of May 14, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 14, 2025, and (ii) 50,600,000 shares of Class A Common Stock issued in connection with the Transaction (as defined below).

| **CUSIP No.** | **988366100** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Jun Wang** | Name of reporting person<br>**Jun Wang** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CHINA** | Citizenship or place of organization<br>**CHINA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**81943800.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**81943800.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**81943800.00** | Aggregate amount beneficially owned by each reporting person<br>**81943800.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**48.1%** | Percent of class represented by amount in Row (11)<br>**48.1%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Comments for "Aggregate amount beneficially owned by each reporting person": Represents 81,943,800 shares of Class A Common Stock of the Issuer directly held by Flydragon International Limited, an entity 100% owned and controlled by Jun Wang. 
 Comment for "Percent of class represented by amount in Row (11)": This percentage is based on an aggregate of 170,416,343 shares of Class A Common Stock, consisting of (i) 119,816,343 shares of Class A Common Stock outstanding as of May 14, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 14, 2025, and (ii) 50,600,000 shares of Class A Common Stock issued in connection with the Transaction (as defined below).

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Class A Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
Yubo International Biotech Limited

**(c) Address of Issuer's Principal Executive Offices:**
1102, 11th Floor, Building 2, No.10, Chaoyang Park S. Rd., Chaoyang District, BEIJING, F4, 100026

This Amendment No. 1 (this "Amendment No. 1") to Schedule 13D amends and supplements certain statements on Schedule 13D originally filed with the U.S. Securities and Exchange Commission (the "SEC") on January 21, 2021 (the "Schedule 13D"), by (i) Flydragon International Limited, a company organized under the laws of British Virgin Islands ("FlyDragon"), and (ii) Mr. Jun Wang, an individual (together with Flydragon, the "Reporting Persons"), as specifically set forth herein. Except as otherwise specified in this Amendment No. 1, all other items of the Schedule 13D remain unchanged in all material respects. Capitalized terms used but not otherwise defined herein have the respective meanings ascribed to them in the Schedule 13D.

**Item 4. Purpose of Transaction**

Item 4 of the Schedule 13D is hereby supplemented by the addition of the following information: 
 
 Securities Purchase Agreement
 
 The subsection entitled "Securities Purchase Agreement" under Item 3 above is hereby incorporated by reference.

**Item 5. Interest in Securities of the Issuer**

**(a)**
See rows (11) and (13) of the cover pages to this Amendment No. 1 for the aggregate number of shares of Class A Common Stock and percentage of shares of Class A Common Stock beneficially owned by each of the Reporting Persons.

**(b)**
See rows (7) through (10) of the cover pages to this Amendment No. 1 for the number of shares of Class A Common Stock as to which each of the Reporting Persons has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

**(c)**
Except as set forth herein, the Reporting Persons have not effected any transactions during the past sixty (60) days in any shares of Class A Common Stock.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Flydragon International Ltd

**Signature:** /s/ Jun Wang

**Name/Title:** Sole Director

**Date:** 07/25/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Jun Wang

**Signature:** /s/ Jun Wang

**Name/Title:** Jun Wang

**Date:** 07/25/2025